Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL440664 | 0.99 | KMT2A (0.40) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| SCHEMBL405852 | 0.89 | KMT2A (0.43) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| Hydrochloric Acid SCHEMBL440635 | 0.88 | KMT2A (0.43) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| Etiguanfacine SCHEMBL406264 | 0.82 | ALDH1A1 (0.48) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| Guanfacine SCHEMBL437729 | 0.82 | KMT2A (0.40) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| SCHEMBL405969 | 0.81 | KMT2A (0.42) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| SCHEMBL406227 | 0.81 | KMT2A (0.43) | KMT2ASMN1; SMN2MAPK1AKR1B1ALDH1A1 | |
| Etiguanfacine SCHEMBL440827 | 0.81 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| Guanfacine SCHEMBL437826 | 0.81 | ADRA2A (0.39) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA | |
| Hydrochloric Acid SCHEMBL442697 | 0.81 | KMT2A (0.41) | KMT2ASMN1; SMN2MAPK1AKR1B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012035346-A1 | PRODRUGS OF GUANFACINE | SHIRE, LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065152-A1 | PRODRUGS OF GUANFACINE | UGT1A6, GDA, UGT1A3 | KMT2A 1095/4885SMN1; SMN2 1309/4885MAPK1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.